Journal of SAFOMS

Register      Login

VOLUME 1 , ISSUE 1 ( January-June, 2013 ) > List of Articles

REVIEW ARTICLE

Atrophic Vaginitis: Diagnosis and Treatment

Surveen Ghumman

Citation Information : Ghumman S. Atrophic Vaginitis: Diagnosis and Treatment. J South Asian Feder Menopause Soc 2013; 1 (1):4-12.

DOI: 10.5005/jp-journals-10032-1002

Published Online: 01-06-2013

Copyright Statement:  Copyright © 2013; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. The role of local vaginal estrogens for the treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14(3):357-69.
  2. Urogenital atrophy-prevention and treatment. Pharmacotherapy 2001;21:464-80.
  3. Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50-75 years. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:9-14.
  4. A study on urogenital complaints of postmenopausal women aged 50 and over. Acta Obstet Gynecol Scand 2005;84(1):72-78.
  5. Prevalence of genitourinary and other climacteric symptoms in 61-yearold women. Maturitas 1996;24(1-2):31-36.
  6. The vaginal epithelium in the postmenopause-cytology, histology and pH as methods of assessment. Maturitas 1995;21(1):51-56.
  7. Cigarette smoking and vaginal atrophy in postmenopausal women. In vivo. 1996;10(6):597-600.
  8. Cigarette smoking and the degree of maturation of the vaginal squamous epithelium in postmenopausal women. Clin Exp Obstet Gynecol 2001; 28(4):274-76.
  9. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 1983; 249(16):2195-98.
  10. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: Cytomorphology versus computerised cytometry. J Clin Pathol 2002;55(6):446-51.
  11. Vaginal dryness in menopausal women: Clinical characteristics and nonhormonal treatment. Clin Pract Sexuality 1991;7:25-32.
  12. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-63.
  13. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80.
  14. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: A preliminary study. Gyneco Endocrinol 2010;26:404-12.
  15. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Arch Gynecol Obstet 2011; 283(3):539-43.
  16. Effects of red clover isoavones (Promensil) versus placebo on uterine endometrium, vaginal maturation index and the uterine artery in healthy postmenopausal women. Menopause Int 2004;10:17.
  17. Vaginal, endometrial, and reproductive hormone findings: Randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: The Herbal Alternatives for Menopause (HALT) Study. Menopause 2008;15(1):51-58.
  18. The effects of postmenopausal vitamin D treatment on vaginal atrophy. Maturitas 2004;49:334-37.
  19. Menopausal years: The wise woman way-alternative approaches for women vol 30-90. Woodstock, New York: Ash Tree 1992; ISBN 9614620-4-3.
  20. Oral pilocarpine to treat vaginal xerosis associated with chemotherapy-induced amenorrhoea in premenopausal women. J Clin Oncol 2004;22(Suppl):14S, Abstr 8099.
  21. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: An up-to-date overview. Climacteric 2009;12:91-105.
  22. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the hormones and urogenital therapy committee. Obstet Gynecol 1998;92(4 Pt 2):722-27.
  23. Low-dose (0.3 mg) synthetic conjugated estrogens. A is effective for managing atrophic vaginitis. Maturitas 2004;47(1):47-54.
  24. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005; 105:1063-73.
  25. Vaginal estrogen therapy for the treatment of atrophic vaginitis. J Womens Health 2009;18(10):1595-606.
  26. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983;57(1):133-39.
  27. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112(5):1053-60.
  28. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Obstet Gynecol 2008;111(1):67-76.
  29. Minimized estradiol absorption with ultra-low-dose 10 mg 17b estradiol vaginal tablets. Climacteric 2010;13:219-27.
  30. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13:99-107.
  31. Vaginal administration of low-dose conjugated estrogens: Systemic absorption and effects on the endometrium. Obstet Gynecol 1994;84(2):215-18.
  32. Efficacy and safety of low-dose regimens of conjugated estrogen cream administered vaginally. Menopause 2009;16:719-27.
  33. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996;174(1 Pt 1):85-92.
  34. Oestradiolreleasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993;16(2):145-54.
  35. Local oestrogen therapy for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006(4):CD 001500.
  36. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;(16):30-36.
  37. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency-a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15(2):121-27.
  38. Endometrial safety of ultralow- dose Vagifem 10 mg in postmenopausal women with vaginal atrophy. Climacteric 2010;13:228-37.
  39. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:883-92.
  40. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010;116(4):876-83.
  41. Vaginal estrogen preparations: A review of safety and efficacy for vaginal atrophy. J Womens Health (Larchmt). 2002;11(10):857-77.
  42. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17(1):194-203.
  43. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45-52.
  44. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17(2):281-89.
  45. Effects of bazedoxifene/ conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010;13(2):132-40.
  46. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms. Curr Opin Investig Drugs 2010;11(4):464-71.
  47. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 2010;7: 1284-90.
  48. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907-22.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.